Vera Therapeutics (NASDAQ:VERA) Announces Quarterly Earnings Results

Key Points

• Vera Therapeutics beat quarterly earnings expectations, reporting an adjusted loss of $1.52 per share versus the consensus estimate of a $1.58 loss.
• Shares fell $1.31 to $31.58 during Monday trading, while the company maintained strong liquidity with current and quick ratios of 13.64 and a debt-to-equity ratio of 0.15.
• Analyst sentiment remained broadly positive, with 11 Buy ratings, one Hold and one Sell, producing a “Moderate Buy” consensus and an average price target of $84.58; institutional investors own 99.21% of the stock.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) issued its earnings results on Monday. The company reported ($1.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.58) by $0.06, FiscalAI reports.

Vera Therapeutics Stock Performance

Shares of VERA traded down $1.31 during trading hours on Monday, hitting $31.58. The stock had a trading volume of 1,036,132 shares, compared to its average volume of 1,432,085. The company has a debt-to-equity ratio of 0.15, a current ratio of 13.64 and a quick ratio of 13.64. Vera Therapeutics has a 12 month low of $19.28 and a 12 month high of $56.05. The firm has a market capitalization of $2.27 billion, a PE ratio of -5.70 and a beta of 0.92. The stock has a fifty day moving average price of $36.58 and a 200 day moving average price of $39.02.

Insiders Place Their Bets

In other Vera Therapeutics news, CEO Marshall Fordyce sold 46,250 shares of the stock in a transaction dated Tuesday, July 7th. The stock was sold at an average price of $42.30, for a total value of $1,956,375.00. Following the transaction, the chief executive officer owned 151,994 shares of the company's stock, valued at approximately $6,429,346.20. This represents a 23.33% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 83,250 shares of company stock valued at $3,337,770 over the last 90 days. 15.90% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Vera Therapeutics

Several institutional investors have recently made changes to their positions in VERA. Price T Rowe Associates Inc. MD grew its position in Vera Therapeutics by 49.0% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 5,461,976 shares of the company's stock valued at $276,595,000 after buying an additional 1,795,537 shares during the period. Deerfield Management Company L.P. boosted its stake in shares of Vera Therapeutics by 8.8% during the 3rd quarter. Deerfield Management Company L.P. now owns 3,641,157 shares of the company's stock worth $105,812,000 after acquiring an additional 293,040 shares during the last quarter. Vestal Point Capital LP grew its position in shares of Vera Therapeutics by 24.0% during the 2nd quarter. Vestal Point Capital LP now owns 3,100,000 shares of the company's stock valued at $73,036,000 after acquiring an additional 600,000 shares during the period. State Street Corp grew its position in shares of Vera Therapeutics by 14.7% during the 4th quarter. State Street Corp now owns 2,676,600 shares of the company's stock valued at $135,543,000 after acquiring an additional 343,017 shares during the period. Finally, Integral Health Asset Management LLC increased its stake in shares of Vera Therapeutics by 5.9% in the 4th quarter. Integral Health Asset Management LLC now owns 1,800,000 shares of the company's stock worth $91,152,000 after purchasing an additional 100,000 shares in the last quarter. Institutional investors own 99.21% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages have commented on VERA. Weiss Ratings reiterated a "sell (d-)" rating on shares of Vera Therapeutics in a research note on Friday, July 17th. William Blair reaffirmed an "outperform" rating on shares of Vera Therapeutics in a report on Tuesday, June 2nd. Guggenheim lifted their price objective on Vera Therapeutics from $56.00 to $76.00 and gave the stock a "buy" rating in a report on Wednesday, July 8th. Evercore set a $91.00 target price on Vera Therapeutics in a research report on Friday, May 15th. Finally, Jefferies Financial Group restated a "buy" rating and set a $60.00 target price on shares of Vera Therapeutics in a research note on Tuesday, June 2nd. Eleven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $84.58.

About Vera Therapeutics

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body's own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source